[1] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7 A30. [2] Watanabe Y, Yoshimura K, Yoshikawa v, et al. A stem cell medium containing neural stimulating factor induces a pancreatic cancer stem-like cell-enriched population[J]. Int J Oncol, 2014, 45(5):1857-1866. [3] Xu L. Cancer stem cell in the progression and therapy of pancreatic cancer[J]. Front Biosci:Landmark Ed, 2013, 18:795-802. [4] Weygant N, Qu D, Berry W L, et al. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1[J]. Mol Cancer, 2014, 13:103. [5] Bailey J M, Alsina J, Rasheed Z A, et al. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer[J]. Gastroenterology, 2014, 146(1):245-256. [6] Nguyen C B, Houchen C W, Ali N. APSA Awardee Submission:tumor/cancer stem cell marker doublecortin-like kinase 1 in liver diseases[J]. Exp Biol Med (Maywood), 2017, 242(3):242-249. [7] De Luca A, Maiello M R, D'Alessio A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways:role in cancer pathogenesis and implications for therapeutic approaches[J]. Expert Opin Ther Targets, 2012, 16(Suppl 2):S17-27. [8] Westphalen C B, Takemoto Y, Tanaka T, et al. Dclk1 defines quiescent pancreatic progenitors that promote injury-induced regeneration and tumorigenesis[J]. Cell Stem Cell, 2016, 18(4):441-455. [9] Gagliardi G, Goswami M, Passera R, et al. DCLK1 immunoreactivity in colorectal neoplasia[J]. Clin Exp Gastroenterol, 2012, 5:35-42. [10] Mohammadi Y, Tavangar S M, Saidijam M, et al. DCLK1 plays an important role in colorectal cancer tumorgenesis through the regulation of miR-200c[J]. Biomed Pharmacother, 2018, 103:301-307. [11] Weygant N, Qu D, May R, et al. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma[J]. Oncotarget, 2015, 6(4):2193-2205. [12] Vedeld H M, Skotheim R I, Lothe R A, et al. The recently suggested intestinal cancer stem cell marker DCLK1 is an epigenetic biomarker for colorectal cancer[J]. Epigenetics, 2014, 9(3):346-350. [13] Bubici C, Papa S. JNK signalling in cancer:in need of new, smarter therapeutic targets[J]. Br J Pharmacol, 2014, 171(1):24-37. [14] Chen F. JNK-induced apoptosis, compensatory growth, and cancer stem cells[J]. Cancer Res, 2012, 72(2):379-386. [15] Takahashi R, Hirata Y, Sakitani K, et al. Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer[J]. Cancer Sci, 2013, 104(3):337-344. [16] 荆薇, 宋娜,车晓芳,等.DNMT3a对胰腺癌细胞吉西他滨敏感性的影响[J].中国医科大学学报,2018,47(10):900-904. |